These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 33142230)

  • 1. Combined intake of glucose-and lipid-lowering medications further elevates plasma levels of PCSK9 in type 2 diabetes patients.
    Awadallah S; Taneera J; Mohammed AK; Unnikannan H; Sulaiman N
    Diabetes Metab Syndr; 2020; 14(6):2087-2092. PubMed ID: 33142230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes.
    Yang SH; Li S; Zhang Y; Xu RX; Guo YL; Zhu CG; Wu NQ; Cui CJ; Sun J; Li JJ
    Diabetes Metab Res Rev; 2016 Feb; 32(2):193-9. PubMed ID: 26377225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of the efficacy of PCSK9 inhibitors and statins on dyslipidemia in patients with type 2 diabetes].
    Wang M; Wu X; Lu XT; Li X
    Zhonghua Yi Xue Za Zhi; 2022 Oct; 102(37):2944-2949. PubMed ID: 36207870
    [No Abstract]   [Full Text] [Related]  

  • 4. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
    Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
    J Atheroscler Thromb; 2022 Jan; 29(1):24-37. PubMed ID: 33342939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Serum PCSK9 Levels in Subjects with Normoglycemia, Impaired Fasting Glucose, and Impaired Glucose Tolerance.
    Han E; Cho NH; Moon SS; Cho H
    Endocrinol Metab (Seoul); 2020 Jun; 35(2):480-483. PubMed ID: 32615732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis.
    Cao YX; Liu HH; Dong QT; Li S; Li JJ
    Diabetes Obes Metab; 2018 Jun; 20(6):1391-1398. PubMed ID: 29377473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study.
    Shi J; Zhang W; Niu Y; Lin N; Li X; Zhang H; Hu R; Ning G; Fan J; Qin L; Su Q; Yang Z
    Cardiovasc Diabetol; 2020 Dec; 19(1):209. PubMed ID: 33302966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin A levels are decreased but not influenced by glucose- or lipid-lowering medications in subjects with type 2 diabetes.
    Taneera J; Awadallah S; Khader Mohammed A; Unnikannan H; Sulaiman N
    Saudi J Biol Sci; 2021 Jan; 28(1):572-577. PubMed ID: 33424341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
    Fischer LT; Hochfellner DA; Knoll L; Pöttler T; Mader JK; Aberer F
    Cardiovasc Diabetol; 2021 Apr; 20(1):89. PubMed ID: 33894772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSK9 in diabetic kidney disease.
    Elewa U; Fernández-Fernández B; Mahillo-Fernández I; Martin-Cleary C; Sanz AB; Sanchez-Niño MD; Ortiz A
    Eur J Clin Invest; 2016 Sep; 46(9):779-86. PubMed ID: 27438893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL.
    Hanefeld M; Traylor L; Gao L; Landgraf W
    Cardiovasc Diabetol; 2017 May; 16(1):66. PubMed ID: 28526014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
    Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
    Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
    Wang Y; Ye J; Li J; Chen C; Huang J; Liu P; Huang H
    Cardiovasc Diabetol; 2016 Feb; 15():19. PubMed ID: 26833058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population.
    Guo W; Gong Y; Gu Y; Fu Z; Fan H; Gao B; Zhu X; Fu J; Zhao Y; Sun M; Liu X; Jiang XC; Yang T; Zhou H
    Lipids Health Dis; 2018 Jan; 17(1):15. PubMed ID: 29343301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients.
    Kappelle PJ; Lambert G; Dullaart RP
    Atherosclerosis; 2011 Feb; 214(2):432-5. PubMed ID: 21122860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome components among young adult females.
    Hasan H; Attlee A; Raigangar V; Madkour M; Awadallah S
    Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S337-S341. PubMed ID: 28283395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
    Arsenault BJ; Petrides F; Tabet F; Bao W; Hovingh GK; Boekholdt SM; Ramin-Mangata S; Meilhac O; DeMicco D; Rye KA; Waters DD; Kastelein JJP; Barter P; Lambert G
    J Clin Lipidol; 2018; 12(1):130-136. PubMed ID: 29103916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.
    El Khoury P; Roussel R; Fumeron F; Abou-Khalil Y; Velho G; Mohammedi K; Jacob MP; Steg PG; Potier L; Ghaleb Y; Elbitar S; Ragot S; Andreata F; Caligiuri G; Hadjadj S; Boileau C; Marre M; Abifadel M; Varret M; Hansel B
    Diabetes Obes Metab; 2018 Apr; 20(4):943-953. PubMed ID: 29205760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes.
    Laugier-Robiolle S; Vergès B; Le Bras M; Gand E; Bouillet B; Saulnier PJ; Le May C; Pichelin M; Maréchaud R; Petit JM; Hadjadj S; Cariou B
    Diabetes Obes Metab; 2017 Mar; 19(3):448-451. PubMed ID: 27804190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.